Publication Name	World Journal of Stem Cells
Manuscript ID	114825
Country	France

Category	Cell Biology
Manuscript Type	Editorial
Article Title	Harnessing CD146-positive mesenchymal stromal cells for precision therapy in acute respiratory distress syndrome
Manuscript Source	Invited Manuscript
All Author List	Özlem Tomsuk
Funding Agency and Grant Number	Funding Agency Grant Number Scientific and Technological Research Council of Türkiye (TÜBİTAK) Under the International Postdoctoral Research Fellowship Program (2219) 1059B192400980 the National Postdoctoral Research Fellowship Program (2218) 122C158
Corresponding Author	Özlem Tomsuk, PhD, Senior Postdoctoral Fellow, Senior Scientist, Institut de Recherche en Cancérologie de Montpellier (IRCM), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut du Cancer de Montpellier (ICM), University of Montpellier, 124 Avenue des Apothicaires, Montpellier 34090, France. ozlem.tomsuk@inserm.fr
Key Words	Acute respiratory distress syndrome; Mesenchymal stromal cells; CD146; Nuclear factor kappa B/cyclooxygenase-2 signaling pathway; Extracellular vesicles; Endothelial barrier repair; Precision medicine
Core Tip	Acute respiratory distress syndrome remains a major significant clinical challenge for translational researchers because of its high mortality and paucity of effective therapies. Mesenchymal stromal cells (MSCs) present a promising approach for immunomodulation and barrier repair. However, heterogeneity within cell populations result in variable clinical efficacy. This editorial endorses the study by Zhang et al, which highlights greater therapeutic efficacy of the CD146+ MSC subpopulation through nuclear factor kappa B-mediated paracrine regulation. Furthermore, the authors highlight future directions including phenotype-focused manufacturing, multi-marker integration, and cell-free therapies based on extracellular vesicles or secretomes illustrating the potential of MSC-based interventions for precision medicine.
Citation	Tomsuk Ö. Harnessing CD146-positive mesenchymal stromal cells for precision therapy in acute respiratory distress syndrome. World J Stem Cells 2025; In press

Received	2025-09-29 01:31
Peer-Review Started	2025-09-29 01:31
First Decision by Editorial Office Director	2025-10-10 07:45
Return for Revision	2025-10-10 07:45
Revised	2025-10-29 21:20
Publication Fee Transferred
Second Decision by Editor	2025-12-01 02:50
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2025-12-02 08:53
Articles in Press	2025-12-02 08:53
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1948-0210 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com